1. Home
  2. SWX vs IMVT Comparison

SWX vs IMVT Comparison

Compare SWX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southwest Gas Holdings Inc. (DE)

SWX

Southwest Gas Holdings Inc. (DE)

HOLD

Current Price

$90.48

Market Cap

6.3B

Sector

Utilities

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$37.88

Market Cap

7.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWX
IMVT
Founded
1931
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
7.3B
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
SWX
IMVT
Price
$90.48
$37.88
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
$87.40
$33.00
AVG Volume (30 Days)
500.3K
1.5M
Earning Date
05-05-2026
05-28-2026
Dividend Yield
2.70%
N/A
EPS Growth
120.29
N/A
EPS
1.91
N/A
Revenue
$5,433,972,000.00
N/A
Revenue This Year
$18.48
N/A
Revenue Next Year
$2.61
N/A
P/E Ratio
$46.65
N/A
Revenue Growth
9.56
N/A
52 Week Low
$72.43
$14.32
52 Week High
$94.43
$39.28

Technical Indicators

Market Signals
Indicator
SWX
IMVT
Relative Strength Index (RSI) 58.42 69.37
Support Level $87.14 $25.13
Resistance Level $93.93 N/A
Average True Range (ATR) 1.46 1.44
MACD 0.29 0.42
Stochastic Oscillator 90.44 85.29

Price Performance

Historical Comparison
SWX
IMVT

About SWX Southwest Gas Holdings Inc. (DE)

Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: